MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025)
MapLight Therapeutics (MPLT) reported Free Cash Flow of -$47.2 million for Q4 2025, down 118.6% on a YoY basis from $253.8 million in Q4 2024, and down 118.6% sequentially from -$21.6 million in Q4 2024.
MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Free Cash Flow data on file, last reported at -$47.2 million in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow fell 118.6% year-over-year to -$47.2 million; the trailing twelve-month figure through Dec 2025 stood at -$68.8 million (changed N/A YoY), and the FY2025 full-year result was -$138.6 million, down 74.17% from the prior year.
- Free Cash Flow retreated to -$47.2 million in Q4 2025, from -$21.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$21.6 million in Q4 2024 to a low of -$47.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | -47.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47.21 Mn |
| Dec 31, 2025 | -47.21 Mn |
| Dec 31, 2024 | -21.59 Mn |
| Dec 31, 2024 | -21.59 Mn |